Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome
Authors:
- Eva Maria WendelEWEva Maria Wendel
- Helen Sophie ThonkeHTHelen Sophie Thonke
- Annikki BertoliniABAnnikki Bertolini
- Matthias BaumannMBMatthias Baumann
- Astrid BlaschekABAstrid Blaschek
- Andreas MerkenschlagerAMAndreas Merkenschlager
- Michael KarenfortMKMichael Karenfort
- Barbara KornekBKBarbara Kornek
- Christian LechnerCLChristian Lechner
- Daniela PohlDPDaniela Pohl
- Martin PritschMPMartin Pritsch
- Kathrin SchandaKSKathrin Schanda
Open Access
- 13 October 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 9 (6)
Abstract
Background and Objective The spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorder (MOGAD) comprises monophasic diseases such as acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), and transverse myelitis and relapsing courses of these presentations. Persistently high MOG antibodies (MOG immunoglobulin G [IgG]) are found in patients with a relapsing disease course. Prognostic factors to determine the clinical course of children with a first MOGAD are still lacking. The objective of the study is to assess the clinical and laboratory prognostic parameters for a risk of relapse and the temporal dynamics of MOG‐IgG titers in children with MOGAD in correlation with clinical presentation and disease course. Methods In this prospective multicenter hospital-based study, children with a first demyelinating attack and complete data set comprising clinical and radiologic findings, MOG-IgG titer at onset, and clinical and serologic follow-up data were included. Serum samples were analyzed by live cell-based assay, and a titer level of ≥1:160 was classified as MOG-IgG–positive. Results One hundred sixteen children (f:m = 57:59) with MOGAD were included and initially diagnosed with ADEM (n = 59), unilateral ON (n = 12), bilateral ON (n = 16), myelitis (n = 6), neuromyelitis optica spectrum disorder (n = 8) or encephalitis (n = 6). The median follow-up time was 3 years in monophasic and 5 years in relapsing patients. There was no significant association between disease course and MOG-IgG titers at onset, sex, age at presentation, or clinical phenotype. Seroconversion to MOG-IgG–negative within 2 years of the initial event showed a significant risk reduction for a relapsing disease course. Forty-two/one hundred sixteen patients (monophasic n = 26, relapsing n = 16) had serial MOG-IgG testing in years 1 and 2 after the initial event. In contrast to relapsing patients, monophasic patients showed a significant decrease of MOG-IgG titers during the first and second years, often with seroconversion to negative titers. During the follow-up, MOG-IgG titers were persistently higher in relapsing than in monophasic patients. Decrease in MOG-IgG of ≥3 dilution steps after the first and second years was shown to be associated with a decreased risk of relapses. In our cohort, no patient experienced a relapse after seroconversion to MOG-IgG–negative. Discussion In this study, patients with declining MOG-IgG titers, particularly those with seroconversion to MOG-IgG–negative, are shown to have a significantly reduced relapse risk.Keywords
This publication has 29 references indexed in Scilit:
- Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in childrenNeurology Neuroimmunology & Neuroinflammation, 2015
- Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypeJournal of Neuroinflammation, 2015
- Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoproteinJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonNeurology Neuroimmunology & Neuroinflammation, 2014
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitionsMultiple Sclerosis Journal, 2013
- Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patientsMultiple Sclerosis Journal, 2012
- Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disordersJournal of Neuroinflammation, 2011
- Antibodies to MOG are transient in childhood acute disseminated encephalomyelitisNeurology, 2011
- Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseasesClinical Immunology, 2011
- Therapeutic plasmapheresisSeminars in Veterinary Medicine and Surgery: Small Animal, 1997